Clinical Hematology International

Volume 1, Issue 3, September 2019, Pages 161 - 167

Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument

Authors
Sandhya R. Panch1, *, , Opal L. Reddy1, , Katherine Li1, Thejaswi Bikkani1, Anusha Rao1, Swathi Yarlagadda1, Steven Highfill1, Daniel Fowler2, Richard W. Childs3, Minocher Battiwalla3, John Barrett3, Andre Larochelle3, Crystal Mackall4, Nirali Shah5, David F. Stroncek1
1Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland, USA
2Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
3Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
4Cancer Immunology and Immunotherapy Program, Stanford Cancer Institute, Palo Alto, California, USA
5Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

co-first authors

*Corresponding author. Postal address: Medical Director, Cell Processing Section, Department of Transfusion Medicine, Clinical Center/National Institutes of Health, Building 10, 3C-720D, Bethesda, Maryland, USA. Tel.: 301-827-3509; Ph.: 301-335-1946; Fax: 301-402-1360. Email: sandhya.panch@nih.gov
Corresponding Author
Sandhya R. Panch
Received 19 March 2019, Accepted 26 May 2019, Available Online 1 September 2019.
DOI
https://doi.org/10.2991/chi.d.190529.001How to use a DOI?
Keywords
CliniMACS; Cell selection; CD34; Cell purity; Cell recovery
Abstract

Cell separation technologies play a vital role in the graft engineering of hematopoietic cellular fractions, particularly with the rapid expansion of the field of cellular therapeutics. The CliniMACS Plus Instrument (Miltenyi Biotec) utilizes immunomagnetic techniques to isolate hematopoietic progenitor cells (HPCs), T cells, NK cells, and monocytes. These products are ultimately used for HPC transplantation and for the manufacture of adoptive immunotherapies. We evaluated the viable cell recovery and cell purity of selections and depletions performed on the CliniMACS Plus over a 10-year period at our facility, specifically assessing for the isolation of CD34+, CD4+, CD3+/CD56+, CD4+/CD8+, and CD25+ cells. Additionally, patient- and instrument-related factors affecting these parameters were examined. Viable cell recovery ranged from 32.3 ± 10.2% to 65.4 ± 15.4%, and was the highest for CD34+ selections. Cell purity ranged from 86.3 ± 7.2% to 99.0 ± 1.1%, and was the highest for CD4+ selections. Undesired cell fractions demonstrated a range of 1.2 ± 0.45 to 5.1 ± 0.4 log reductions. Red cell depletions averaged 2.12 ± 0.68 logs, while platelets were reduced by an average of 4.01 ± 1.57 logs. Donor characteristics did not impact viable cell recovery or cell purity for CD34+ or CD4+ cell enrichments; however, these were affected by manufacturing variables, including tubing size, bead quantity, and whether preselection platelet washes were performed. Our data demonstrate the efficient recovery of hematopoietic cellular fractions on the CliniMACS Plus that may be optimized by adjusting manufacturing variables.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Volume-Issue
1 - 3
Pages
161 - 167
Publication Date
2019/09/01
ISSN (Online)
2590-0048
DOI
https://doi.org/10.2991/chi.d.190529.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Sandhya R. Panch
AU  - Opal L. Reddy
AU  - Katherine Li
AU  - Thejaswi Bikkani
AU  - Anusha Rao
AU  - Swathi Yarlagadda
AU  - Steven Highfill
AU  - Daniel Fowler
AU  - Richard W. Childs
AU  - Minocher Battiwalla
AU  - John Barrett
AU  - Andre Larochelle
AU  - Crystal Mackall
AU  - Nirali Shah
AU  - David F. Stroncek
PY  - 2019
DA  - 2019/09/01
TI  - Robust Selections of Various Hematopoietic Cell Fractions on the CliniMACS Plus Instrument
JO  - Clinical Hematology International
SP  - 161
EP  - 167
VL  - 1
IS  - 3
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190529.001
DO  - https://doi.org/10.2991/chi.d.190529.001
ID  - Panch2019
ER  -